Human hepatitis viruses-associated cutaneous and systemic vasculitis

Table 3 Comparisons of clinical and outcome profiles in polyarteritis nodosa from various case series with different hepatitis B virus-infected frequencies

Source of cases	No/age1 F%	HBV status	Fever	AM	Skin	PN	GI	Renal	TestisM%	Therapy	Death
Taiwan	12/31, 67%	0%	67%	58%	75%	42%	50%	75%	50%	Az, Cs, Cy, Bio	33%
United Kingdom	17/49, 24%	31%	76%	77%	65%	59%	65%	77%	NA	Cs, Is	38%
United States	53/54, 34%	11%	31%	55%	58%	60%	25%	66%	NA	Cs, Cy	42%
Canada	45/54, 47%	19%	63%	51%	44%	51%	53%	44%	4%	Cs, Cy	53%
South Korea	27/47, 37%	56%	52%	30%	44%	63%	48%	48%	24%	Az, Cs, Cy, Is	15%
France	348/51,37%	35%	64%	59%	50%	74%	38%	51%	17%	Av, Cs, Cy, Is	25%
India	27/38, 26%	26%	52%	37%	37%	82%	30%	59%	30%	Av, Az, Cs, Cy	11%

¹Mean age at disease diagnosis. AM: Articulomuscular; Az: Azathioprine; Av: Antiviral agent; Bio: Biologics; Cs: Corticosteroids; Cy: Cyclophosphamide; F: Female; GI: Gastrointestinal; Is: Immunosuppressive agent, M: Male; NA: Not available; PN: Peripheral neuropathy.